BioMarin Pharmaceutical Inc (BMRN) News
Filter BMRN News Items
BMRN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BMRN News Highlights
- BMRN's 30 day story count now stands at 7.
- Over the past 16 days, the trend for BMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ADD, HUGE and DNLI are the most mentioned tickers in articles about BMRN.
Latest BMRN News From Around the Web
Below are the latest news stories about BIOMARIN PHARMACEUTICAL INC that investors may wish to consider to help them evaluate BMRN as an investment opportunity.
BioMarin strikes deal with Elliott, agrees to review businessUnder pressure from the activist investor, BioMarin will add more independent directors and set up an operational review committee. |
BioMarin settles with Elliott, adds 3 independent directorsBioMarin reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its board and form a committee to review operations. The new Strategic and Operating Review Committee will evaluate the company's business, strategy and operations, financial and capital allocation priorities, and long-term planning and priorities, the company said in a statement. In November, Reuters reported that Elliott owns a stake in BioMarin and had been holding discussions with the company, valued at $18 billion, about possible changes. |
BioMarin Announces Governance Enhancements and Value Creation InitiativesBioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation. |
Insider Sell: EVP, Chief Legal Officer George Davis Sells 13,764 Shares of Biomarin ...Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and delivering therapies for rare genetic diseases, has recently witnessed a significant insider sell by one of its top executives. |
Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?Key Insights The projected fair value for BioMarin Pharmaceutical is US$193 based on 2 Stage Free Cash Flow to Equity... |
Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report?Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Billionaire Louis Bacon’s 10 Stock Picks with Huge Upside PotentialIn this article, we discuss billionaire Louis Bacon’s 10 stock picks with huge upside potential. To skip the details about Mr. Bacon’s life, portfolio performance, and investment strategy, go directly to Billionaire Louis Bacon’s 5 Stock Picks with Huge Upside Potential. Louis Bacon is a macro-trading legend on Wall Street. Macro traders capitalize on financial […] |
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market DipAn 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping. |
Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report?BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Elfun Trusts Sheds Qualcomm in Q3, Embraces New HoldingsInsight into Elfun Trusts (Trades, Portfolio)' Latest Investment Moves and Portfolio Adjustments |